Aflibercept Biosimilar (Boan Biopharma/Luye Pharma）

阿柏西普生物类似药 (山东博安/绿叶制药)

Report date: 2025/12/05 14:12:26

Base Information

Drug NameAflibercept Biosimilar (Boan Biopharma/Luye Pharma）
Drug Alias Name阿柏西普眼内注射溶液博优景LY-09004BA-9101OT-702
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsDiabetic macular oedemaWet age-related macular degeneration
Approved Indications in ChinaDiabetic macular oedemaWet age-related macular degeneration
Original Approved Country/TerritoryMainland China
Original Approved Date2025/11/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Boan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOukang Weishi (Zhejiang) Pharmaceutical Co LtdShandong Boan Biotechnology Co Ltd
Inactive CompaniesLuye Pharma Group Ltd
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeL01XX44S01LA05
Related LinksN/A